Tacrolimus in membranous nephropathy  by Wetzels, J.F.M.
Tacrolimus in membranous
nephropathy
Kidney International (2008) 73, 238; doi:10.1038/sj.ki.5002664
To the Editor: In a recent issue of the Journal, Praga et al.1
reported their experience with tacrolimus monotherapy in
patients with idiopathic membranous nephropathy. The
authors concluded that tacrolimus was a very useful
therapeutic option. This conclusion was based on the
findings of a higher remission rate and a reduced risk of
deterioration of renal function in the treated patients.
However, some of the reported data need clarification.
(1) This study may not be applicable to routine clinical
practice. Most studies included patients with
relatively recent onset of disease. In the study of
Praga et al., the interval between diagnosis and
inclusion in the study was 45 months in the control
group and 58 months in the treated group. Most
patients with idiopathic membranous nephropathy
will develop remission or renal failure within 3 years
after presentation.2
(2) The information on follow-up time is lacking. The
study included patients studied between January
2003 and September 2006. It is therefore unlikely
that all patients have been followed for 30 months.
This information is needed to read Figure 3
correctly. The cumulative incidence of a relapse
may be higher than shown.
(3) The power calculation suggests that the study was
powered to determine differences in remission rate
and not differences in renal failure rate.
Moreover the results are overrated and so is the
conclusion. Tacrolimus treatment did not result in persistent
remissions, since the number of remissions at the end of
follow-up was similar in the treated and the control groups.
The shortlasting decrease of proteinuria may be the
consequence of a hemodynamic effect. Correct interpretation
of these results would be that 18 months of treatment with
tacrolimus did not influence the outcome with respect to
remissions at the end of follow-up. Certainly, the conclusion
reached by the authors is driven by the observed differences
in renal function deterioration. In the control group, six
patients developed a 50% increase of serum creatinine level as
compared to only one in the treated group. One normally
would have expected that differences in renal survival become
evident with longer duration of follow-up. However, Figure 5
shows that the differences between the groups were already
apparent at 6 months after randomization, and that there was
no further change in renal function after 12 months. Patients
who reached the renal failure end point were characterized by
higher age, higher initial serum creatinine concentration, and
higher levels of proteinuria. Table 1 clearly indicates that the
treated and the control groups were not balanced with respect
to these parameters. The control group contained more patients
aged 450 years (48 vs 24%), more patients with glomerular
filtration rate o60 ml min1 (17 vs 4%), and more patients
with severe proteinuria (43 vs 32%). These differences must not
be overlooked; the b error is high in a small-sized study.
Therefore, this study does not allow to conclude that tacro-
limus improves renal survival in patients with idiopathic membra-
nous nephropathy. Thus far, only alkylating agents have been
proven effective in reducing the risk of end-stage renal disease.2–4
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Mortality effect of coronary
calcification and phosphate
binder choice in incident
hemodialysis patients. No good
evidence to promote a general
use of sevelamer
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To the Editor: There is little doubt that coronary calcification
is associated with cardiovascular mortality.
Also, plausible biologic explanations implying disturbed
calcium phosphate metabolisms are available. A practicing
nephrologist may therefore be tempted to switch from the
traditional calcium-based chelators to other alternatives. One
of those attractive alternatives is sevelamer, which has been
shown to reduce coronary calcification.
However, coronary calcification is only a surrogate
marker, and clinical trials with improvement of surrogate
markers may not necessarily be associated with better clinical
outcomes. Worse still, in some of them, just to cite the
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